Fingolimod mitigates synaptic deficits and psychosis-like behavior in APP/PSEN1 mice.

Josh M KrivinkoSusan L EricksonMatthew L MacDonaldMegan E GarverRobert A Sweet

Published in: Alzheimer's & dementia (New York, N. Y.) (2022)

Preclinical studies employing complementary psychosis-associated behavioral assessments and proteomic evaluations across multiple AD-related models are warranted to replicate the current study and further investigate fingolimod as a candidate treatment for psychosis in AD.

Keyphrases

multiple sclerosis
traumatic brain injury
early onset
stem cells
cell therapy
radiation induced
combination therapy
adipose tissue
bone marrow
metabolic syndrome
skeletal muscle
replacement therapy